CCP
ABCL icon

Clarkston Capital Partners’s AbCellera Biologics ABCL Stock Holding History

Clarkston Capital Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,000
Closed -$49.1K – 152
2025
Q1 		$49.1K Hold
22,000
– – ﹤0.01% 146
2024
Q4 		$64.5K Hold
22,000
– – ﹤0.01% 150
2024
Q3 		$57.2K Buy
+22,000
New +$61K ﹤0.01% 146

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Clarkston Capital Partners's ABCL Position: Q2 2025 in Review

Clarkston Capital Partners sold out of AbCellera Biologics (ABCL) in Q2 2025, closing a stake of 22,000 shares — an estimated $49.1K sold.

Clarkston Capital Partners first reported a position in ABCL in Q3 2024 and held it in 3 quarters. The position peaked at $64.5K in Q4 2024. 128 funds tracked by Wall St. Rank hold ABCL as of Q2 2025.

  • Clarkston Capital Partners reported no remaining AbCellera Biologics position as of Q2 2025 after selling out during the quarter.
  • Clarkston Capital Partners sold 22,000 AbCellera Biologics shares in Q2 2025, an estimated $49.1K.
  • Clarkston Capital Partners first reported a position in AbCellera Biologics in Q3 2024 and held it in 3 quarters.
  • Clarkston Capital Partners's AbCellera Biologics position peaked at $64.5K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2025.

Based on Clarkston Capital Partners's 13F filing for Q2 2025, filed 13 Aug 2025.